Bleakley Financial Group LLC Has $40,000 Stake in OmniAb, Inc. (NASDAQ:OABI)

Bleakley Financial Group LLC reduced its position in shares of OmniAb, Inc. (NASDAQ:OABI) by 42.4% in the 4th quarter, Holdings Channel reports. The firm owned 11,229 shares of the company’s stock after selling 8,259 shares during the period. Bleakley Financial Group LLC’s holdings in OmniAb were worth $40,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Choreo LLC bought a new stake in shares of OmniAb during the fourth quarter worth $41,000. CWC Advisors LLC. bought a new stake in shares of OmniAb in the third quarter worth $54,000. Walleye Capital LLC bought a new stake in shares of OmniAb in the third quarter worth $61,000. Intech Investment Management LLC bought a new stake in shares of OmniAb in the third quarter worth $70,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after acquiring an additional 8,909 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

Insider Buying and Selling

In other OmniAb news, CEO Matthew W. Foehr sold 41,811 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $135,467.64. Following the completion of the sale, the chief executive officer now directly owns 3,749,639 shares of the company’s stock, valued at approximately $12,148,830.36. This represents a 1.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Charles S. Berkman sold 25,489 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the sale, the insider now directly owns 343,190 shares of the company’s stock, valued at $1,111,935.60. The trade was a 6.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,826 shares of company stock worth $268,356 in the last quarter. Insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on OABI. Benchmark reaffirmed a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Price Performance

OABI opened at $3.57 on Thursday. OmniAb, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $6.55. The firm has a market capitalization of $504.16 million, a PE ratio of -5.76 and a beta of -0.12. The company’s 50-day moving average is $3.52 and its 200 day moving average is $3.94.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.